NCT03397199

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.

Detailed description

Colorectal cancer is a common clinical gastrointestinal cancer. In addition to the early diagnosis of some patients, approximately 50% of patients have had distant metastases at the time of diagnosis. For patients with advanced colorectal cancer, systemic chemotherapy is the main treatment. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients. We designed the study to explore the possibility of apatinib for Advanced Colorectal Cancer.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Apatinib + S-1	Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.

Timeline

• Start date: 2018-01-09
• Primary completion: 2020-10-01
• Completion: 2021-03-01
• First posted: 2018-01-11
• Last updated: 2020-04-15

Locations

1 site across 1 country: China